An observational study in Endometrial Cancer, DNA Methylation and Cytology, sponsored by Lei Li. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Lei Li · Observational
This study intends to conduct the "Real-world Study on Cervical Cytology Methylation Testing for Endometrial Cancer Screening" project through a multi-center real-world research approach. Led by Peking Union Medical College Hospital, at least 10 institutions will participate in the study. The goal is to complete the enrollment of at least 30 million real-world samples. Focusing on the changes in DNA methylation levels in cervical exfoliated cells as the research entry point, this study aims to provide new ideas and theoretical basis for preventing and treating endometrial cancer by targeting the CDO1/CELF4 double gene methylation. The expectation is to achieve the clinical application of a more optimal endometrial cancer screening protocol, improve the current shortcomings of endometrial cancer screening, make endometrial cancer screening more accurate, effectively reduce the incidence of endometrial cancer, and avoid excessive medical treatment.
1,347 studies on the registry are indexed under Endometrial Neoplasms; 452 are open to participants now.
This study's planned enrollment of 30,000 is above the median of 200 across 328 observational studies indexed under Endometrial Neoplasms.
Browse Endometrial Neoplasms studies →Lei Li is the lead sponsor of 62 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All women asking for Collection of cervical exfoliated cells in hospital situation or in community situation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CDO1m and CELF4m for cervical cancer screening
Number of participants with histopathological diagnosis of endometrial cancer
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.
Of 126 non-industry observational studies under Endometrial Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 206. This study's planned 23 months is below that.
Counting every sponsor, half of 146 studies reached it within 66 months; a quarter within 32 and three quarters within 206.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lei Li